title: New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?
abstract: Lipid abnormalities including increased total cholesterol (TC), triglycerides (TG) and low density lipoprotein cholesterol (LDL-C) have been frequently reported in renal transplantation and could be involved in the high frequency of cardiovascular diseases in this population.
  
  
  METHODS
  Two hundred ninety-five patients were transplanted between January 1995 and October 2000 in our center. Two hundred two patients were included in this study. Seventy-six patients received tacrolimus (Tac), and 126 patients cyclosporine (CsA). Lipid parameters were assessed the day of transplantation and 1 year posttransplantation.
  
  
  RESULTS
  Serum lipids were similar between the two groups at D0. At M12, TC and LDL-C were significantly higher in the CsA group (6.14 +/- 1.37 vs 5.28 +/- 1.32 mmol/L; P < .05 and 3.98 +/- 1.05 vs 3.26 +/- 1.03 mmol/L; P < .05 CsA vs Tac, respectively). TG were comparable in both groups (1.86 +/- 1.07 vs 1.62 +/- 0.92 mmol/L; P = .55; CsA vs Tac). Incidence of de novo hypercholesterolemia was significantly higher in the CsA group (28 vs 8%) whereas incidence of hyperTG was similar in both groups. Prevalence of LDL-C was significantly higher in the CsA group (65% vs 31%; P < .001), whereas there was no difference in high density lipoprotein (HDL)-C levels.
  
  
  CONCLUSIONS
  Mean serum lipid levels and incidence and prevalence of hyperTC, especially LDL-C, was significantly higher in patients receiving CsA when compared with Tac. TG and HDL-C levels were similar. Although the study was retrospective, our results confirm that CsA increases lipid levels, whereas Tac does not.
  
  
  CONCLUSIONS
  Lipid disorders are frequently observed in renal transplant recipients. CsA, but not Tac, significantly increases incidence and prevalence of high TC and LDL-C.
authors.affiliation: Department of Nephrology and Transplantation, Lapeyronie University Hospital, University of Montpellier Medical School, 34295 Montpellier 05, France.
authors.forename: S
authors.initials: S
authors.lastname: Deleuze
authors.forename: V
authors.initials: V
authors.lastname: Garrigue
authors.forename: S
authors.initials: S
authors.lastname: Delmas
authors.forename: G
authors.initials: G
authors.lastname: Chong
authors.forename: I
authors.initials: I
authors.lastname: Swarcz
authors.forename: J P
authors.initials: JP
authors.lastname: Cristol
authors.forename: G
authors.initials: G
authors.lastname: Mourad
mesh_terms: D000328:Adult; D015992:Body Mass Index; D002784:Cholesterol / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects*; D050171:Dyslipidemias / Q000453:epidemiology*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D015995:Prevalence; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D006454:Hemoglobins; D007166:Immunosuppressive Agents; D008055:Lipids; D014280:Triglycerides; D016572:Cyclosporine; D002784:Cholesterol; D016559:Tacrolimus